PLK1 and cancer: Furthermore, since the Plk1 PBD can interact with a variety of structurally diverse phosphoepitope-containing proteins54, it is reasonable to speculate that anti-PBD agents could potentially be optimized so that they selectively inhibit a subset of PBD-dependent interactions, which are enriched in biochemically rewired, Plk1-addicted cancer cells24.